Supramolecular EXP3174–AHU377 Complex to Improve Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for hypertension and heart failure, particularly those involving angiotensin II receptor antagonist metabolites and NEP inhibitors, face challenges such as low bioavailability and ineffective clinical applications due to the limitations of direct administration of EXP3174 and LCZ96/96, necessitating an improved treatment method.
Innovation Solution
A treatment method involving a supramolecular complex of an angiotensin II receptor antagonist metabolite (EXP3174) and an NEP inhibitor (AHU377) administered at specific dosages and frequencies, formulated into tablets or capsules, which enhances the bioavailability and efficacy of both components.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If EXP3174 and LCZ96/96 are administered directly, then the treatment approach is simple, but the bioavailability is low and clinical effectiveness is insufficient
Solution Approach 1:
The patent applies composite material principle by creating a supramolecular complex combining EXP3174 (angiotensin II receptor antagonist metabolite) with LCZ96/96 (NEP inhibitor) in a specific molar ratio. This composite formulation enhances bioavailability and clinical effectiveness compared to direct administration of individual components, while maintaining a manageable formulation structure through defined stoichiometric relationships.
2Reliability
If the dosage of the complex is increased to improve therapeutic effect, then blood pressure lowering and heart failure treatment efficacy improve, but the risk of adverse effects may increase
Solution Approach 1:
The patent applies parameter change principle by optimizing the dosage range of the complex to 60-500 mg per day and establishing a specific molar ratio (1:0.25 to 4) between EXP3174 and LCZ96/96. These parameter optimizations enable dose-dependent therapeutic effects for blood pressure lowering and heart failure treatment while maintaining an acceptable safety profile, balancing efficacy improvement with adverse effect control.
Data Source
AI summary
The present application belongs to the technical field of drug application, relates to a treatment method using a complex of an angiotensin II receptor antagonist metabolite and an NEP inhibitor, and specifically relates to the dosage of the drug.